5,8,11,14,17-eicosapentaenoyl chloride | 85916-97-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 5,8,11,14,17-eicosapentaenoyl chloride
• 英文别名: icosa-5,8,11,14,17-pentaenoyl chloride
• CAS: 85916-97-8
• 化学式: C₂₀H₂₉ClO
• 分子量: 320.903
• InChiKey: MPMQIVKVFWGFFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  22
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,8,11,14,17-eicosapentaenoyl chloride 在 溶剂黄146 、 三乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 53.0h， 生成 glyceryl-1-(5,8,11,14,17-eicosapentaenoate)
  参考文献：
  名称：

  Compositions and methods for the treatment of urea cycle disorders and gout

  摘要：

  本文所披露的化合物包括I式、II式、III式、IV式、V式、VI式和VII式，或其药物可接受的组合物和盐，以及其多晶形、对映异构体、立体异构体、溶剂化物和水合物。这些药物组合物可以制成口服、延迟释放或缓释、经口黏膜、糖浆、局部用药、注射、皮下注射、口服溶液、直肠给药、纳米粒子、颊粘膜给药或经皮给药的制剂。这些组合物可用于治疗尿素循环障碍和痛风或其相关并发症。

  公开号：

  US09475747B1
• 作为产物：
  描述：

  5,8,11,14,17-二十碳五烯酸 在 草酰氯 作用下， 以 氯仿 为溶剂， 反应 3.0h， 生成 5,8,11,14,17-eicosapentaenoyl chloride
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS

  摘要：

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗粘膜炎的方法可以制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗与消化道内膜疼痛性炎症和溃疡相关的黏膜疾病。

  公开号：

  US20150307446A1

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：KANDULA Mahesh

  公开号：US20150119409A1

  公开（公告）日：2015-04-30

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g. intermittent claudication), and the brain (hence its use in vascular dementia), venous disease, Peyronie's disease, neuropathic injuries, strokes, sickle cell disease, nausea and headaches in the mountains (altitude sickness), non-alcoholic steatohepatitis and alcoholic liver disease, fibrotic lesions induced by radiation therapy for breast cancer, cytokine release syndrome, cancer, type 1 diabetes and type 2 diabetes, asthma, bronchodilation, kidney diseases, renal protection, vascular ischemia, neuroprotection, vasodilation, Alzheimer's disease, dementia, stroke, and treatment of endometriosis.

  本发明涉及式I化合物或其药学上可接受的盐，以及多晶型物、溶剂化物、对映体、立体异构体和其水合物。包含有效量的式I化合物的药物组合物，以及用于治疗或预防炎症性疾病的方法可以被配制成口服、颊、直肠、局部、透皮、经粘膜、静脉内、肠胃外给药、糖浆或注射剂。这些组合物可用于治疗由于四肢动脉阻塞引起的间歇性跛行，以及血管性痴呆，改善通过外周血管的血流，从而有助于手臂和腿部的血液循环（例如间歇性跛行），以及大脑（因此用于血管性痴呆），静脉疾病，佩罗尼氏病，神经损伤，中风，镰状细胞病，山区恶心和头痛（高原病），非酒精性脂肪性肝炎和酒精性肝病，由乳腺癌放射治疗引起的纤维化病变，细胞因子释放综合征，癌症，1型糖尿病和2型糖尿病，哮喘，支气管扩张，肾脏疾病，肾脏保护，血管缺血，神经保护，血管舒张，阿尔茨海默病，痴呆，中风，以及治疗子宫内膜异位症。
• [EN] COMPOSITIONS AND METHODS FOR SUPPRESSION OF CARBONIC ANHYDRASE ACTIVITY<br/>[FR] COMPOSITIONS ET MÉTHODES INHIBANT L'ACTIVITÉ DE L'ANHYDRASE CARBONIQUE
  申请人：KANDULA MAHESH

  公开号：WO2013167994A1

  公开（公告）日：2013-11-14

  Provided are the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing or modulating carbonic anhydrase activity in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral admimstration, syrup, or injection. Such compositions may be used to treatment of glaucoma, epileptic seizures, Idiopathic intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, periodic paralysis and dural ectasia, congestive heart failure, drug induced edema, diuretic, intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.

  提供的是具有式(I)或其药用可接受盐的化合物，以及其多型体、溶剂合物、对映体、立体异构体和水合物。包括有效量的式(I)化合物的药物组合物，以及用于治疗、预防或调节疾病中碳酸酐酶活性的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂。这些组合物可用于治疗青光眼、癫痫发作、特发性颅内高压（假性脑膜炎）、高山病、胱氨酸尿症、周期性麻痹和硬膜扩张、充血性心力衰竭、药物诱导性水肿、利尿剂、因肢体动脉阻塞而导致的间歇性跛行以及血管性痴呆症的治疗。
• Compositions and methods for the suppression of carbonic anhydrase activity
  申请人：Kandula Mahesh

  公开号：US09284287B1

  公开（公告）日：2016-03-15

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing or modulating carbonic anhydrase activity in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, epileptic seizures, Idiopathic intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, periodic paralysis and dural ectasia, congestive heart failure, drug induced edema, diuretic, intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗、预防或调节疾病中的碳酸酐酶活性的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这些组合物可用于治疗青光眼、癫痫发作、特发性颅内高压（假性脑膜炎）、高原反应、胱氨酸尿症、周期性麻痹和硬膜扩张、充血性心力衰竭、药物诱导性水肿、利尿剂、因肢体动脉阻塞而导致的间歇性跛行以及血管性痴呆的治疗。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
  申请人：Cellix Bio Private Limited

  公开号：US20160120839A1

  公开（公告）日：2016-05-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

  该发明涉及公式I和公式II的化合物或其药用可接受盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。含有公式I或公式II化合物的有效量的药物组合物；以及治疗或预防炎症性肠病的方法可制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻度至中度克罗恩病、类风湿关节炎、炎症性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN
  申请人：Kandula Mahesh

  公开号：US20150141479A1

  公开（公告）日：2015-05-21

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating moderate to severe pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, severe pain, chronic pain, chemotherapy induced pain, epilepsy, glaucoma, arthritis, tooth aches, inflammation, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.

  该发明涉及式I和式II的化合物或其药用盐，以及其多晶体、溶剂合物、对映体、立体异构体和水合物。包含有效量的式I或式II化合物的药物组合物，以及用于治疗、预防或调节疾病中中度至严重疼痛的方法可以制备为口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射。这些组合物可用于治疗疼痛、严重疼痛、慢性疼痛、化疗诱导疼痛、癫痫、青光眼、关节炎、牙痛、炎症、肌肉骨骼疼痛、坐骨神经痛、神经根痛、偏头痛、神经性疼痛、带状疱疹后神经痛、神经痛、多发性硬化症、多发性硬化症、不安腿综合症（RLS）、集束性头痛、抑郁症、纤维肌痛、肌萎缩侧索硬化症（ALS）、抽搐、部分性癫痫、情绪稳定剂和躁郁症的药物组合物。